VYNE Therapeutics announces results from Phase 1a SAD trial for VYN202

VYNE Therapeutics announced positive data from the single ascending dose, SAD, portion of its ongoing Phase 1a trial of VYN202. The Phase 1a trial is a two-part, double-blind, placebo-controlled dose-escalation study in healthy volunteers consisting of SAD and multiple ascending dose, MAD, components to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202. Findings from the SAD portion of the Phase 1a trial to date are as follows: VYN202 Was Generally Well Tolerated Across All Dose Groups; VYN202 Demonstrated Dose-Dependent PK; VYN202 Demonstrated Pharmacodynamic Effects; Phase 1a MAD Portion of Trial Initiated